TY - JOUR
T1 - Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer
T2 - A comparative review
AU - Ranieri, Girolamo
AU - Pantaleo, Marianna
AU - Piccinno, Mariagrazia
AU - Roncetti, Maria
AU - Mutinati, Maddalena
AU - Marech, Ilaria
AU - Patruno, Rosa
AU - Rizzo, Annalisa
AU - Sciorsci, Raffaele Luigi
PY - 2013/11
Y1 - 2013/11
N2 - Tyrosine kinase receptors (TKRs) play a key role in tumour cell proliferation and survival since they are involved in endothelial cell activation leading to tumour neoangiogenesis. In particular, vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (c-KitR), and colony-stimulating factor 1 (CSF-1) are overexpressed or constitutively activated in human and pet malignancies. A variety of small molecule inhibitors targeting specific tyrosine kinases (known as tyrosine kinase inhibitors or TKIs) have recently been approved, or are under investigation, for the treatment of human cancer. TKI application in animal cancer is however relatively recent. This review aims to illustrate the major aspects of tyrosine kinase dysfunctions, with special regard to human and animal cancer of the mammary gland, providing an update on the background of the anti-angiogenic and anti-neoplastic properties of TKIs in human and veterinary cancer.
AB - Tyrosine kinase receptors (TKRs) play a key role in tumour cell proliferation and survival since they are involved in endothelial cell activation leading to tumour neoangiogenesis. In particular, vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (c-KitR), and colony-stimulating factor 1 (CSF-1) are overexpressed or constitutively activated in human and pet malignancies. A variety of small molecule inhibitors targeting specific tyrosine kinases (known as tyrosine kinase inhibitors or TKIs) have recently been approved, or are under investigation, for the treatment of human cancer. TKI application in animal cancer is however relatively recent. This review aims to illustrate the major aspects of tyrosine kinase dysfunctions, with special regard to human and animal cancer of the mammary gland, providing an update on the background of the anti-angiogenic and anti-neoplastic properties of TKIs in human and veterinary cancer.
KW - Angiogenesis
KW - Bitch
KW - Breast cancer
KW - Comparative oncology
KW - Pets
KW - Queen
KW - Tyrosine kinase inhibitors
KW - Tyrosine kinase receptors
KW - Women
UR - http://www.scopus.com/inward/record.url?scp=84885834050&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885834050&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2013.05.009
DO - 10.1016/j.critrevonc.2013.05.009
M3 - Article
C2 - 23768779
AN - SCOPUS:84885834050
VL - 88
SP - 293
EP - 308
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
IS - 2
ER -